NASDAQ · SVRA
Healthcare · Biotechnology
$4.78
Down-$0.13 (-2.72%)
Updated Oct 7, 2026, 12:14 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SVRA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
SVRA closed at $4.78 after 20 trading sessions, down 13.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.85 | $4.915 | $4.71 | $4.78 | 2.86M |
| Oct 2, 2026 | $5.10 | $5.16 | $4.765 | $4.81 | 2.65M |
| Oct 1, 2026 | $5.15 | $5.24 | $5.03 | $5.045 | 2.55M |
| Sep 30, 2026 | $5.15 | $5.24 | $5.05 | $5.16 | 6.05M |
| Sep 29, 2026 | $5.07 | $5.19 | $5.00 | $5.08 | 2.03M |
| Sep 28, 2026 | $4.97 | $5.155 | $4.86 | $5.07 | 4.37M |
| Sep 25, 2026 | $5.08 | $5.18 | $4.87 | $5.00 | 2.45M |
| Sep 24, 2026 | $5.03 | $5.085 | $4.884 | $5.07 | 2.5M |
| Sep 23, 2026 | $5.30 | $5.34 | $4.90 | $5.00 | 3.35M |
| Sep 22, 2026 | $5.52 | $5.525 | $5.29 | $5.30 | 1.41M |
| Sep 21, 2026 | $5.44 | $5.51 | $5.36 | $5.45 | 1.31M |
| Sep 18, 2026 | $5.42 | $5.47 | $5.305 | $5.37 | 2.18M |
| Sep 17, 2026 | $5.23 | $5.465 | $5.22 | $5.42 | 1.23M |
| Sep 16, 2026 | $5.29 | $5.3514 | $5.105 | $5.13 | 1.13M |
| Sep 15, 2026 | $5.33 | $5.34 | $5.175 | $5.26 | 1.3M |
| Sep 14, 2026 | $5.33 | $5.43 | $5.28 | $5.34 | 1.31M |
| Sep 11, 2026 | $5.38 | $5.395 | $5.27 | $5.30 | 1.06M |
| Sep 10, 2026 | $5.34 | $5.46 | $5.24 | $5.32 | 1.53M |
| Sep 9, 2026 | $5.48 | $5.57 | $5.37 | $5.415 | 1.1M |
| Sep 8, 2026 | $5.27 | $5.63 | $5.26 | $5.53 | 1.66M |
The latest Smart Investors Daily articles mentioning SVRA.
Company
Market Activity
Research & News
SVRA research
Company profile and research snapshot.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 23, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 18, 2025 | Wells Fargo | Overweight | — |
| Nov 14, 2025 | Oppenheimer | Outperform | — |
| Nov 13, 2025 | Citizens | Market Outperform | — |
| Oct 23, 2025 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3
Yahoo · Aug 11, 2026
LANGHORNE, Pa., August 11, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update.
Benzinga · Aug 11, 2026
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at ATS Showed
Benzinga · Aug 11, 2026
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SVRA.
